Posted by Michael Wonder on 21 Oct 2022
Silverback Therapeutics announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy (epinephrine nasal spray) for the treatment of allergic reactions (type I) including anaphylaxis
21 October 2022 - neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the US, if approved.
Silverback Therapeutics today announced that the US FDA has accepted for review ARS Pharmaceuticals' new drug application for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs).
